The pharmaceutical company Novo Nordisk deserved less than expected because of the increasing competition for its diabetes and weight loss resources Ozempic and Wegovy.
In its message from Wednesday for the three months of April to June, the manufacturer showed a result before interest and taxes (EBIT) of almost 33.5 billion Danish crowns (approx. 4.5 billion euros). Analysts interviewed by Bloomberg had expected an average of one billion more. The bottom line was that the group also earned a little less than expected with 26.5 billion crowns.
After the Danes had already trimmed their destinations for the year in May, Novo Nordisk recently had recently returned. The reduced forecasts for sales and operational profit have now been confirmed.
The company is currently struggling with problems in particular in its important US business. There, private manufacturers of cheaper copies of its diet treasurer – mostly they are pharmacies – make life difficult for the group.
The weight lowerer Wegovy Wegovy Wegovy, which was much noticed against the background of the weight loss hype of analysts, rinse Novo Nordisk in the second quarter more than expected in the coffers with 19.5 billion crowns. All over the group, the Danes implemented almost 77 billion crowns.
This is how the Novo Nordisk share reacts
The titles of the diabetes specialist slipped down to four years in Copenhagen on Wednesday afternoon and ultimately lost 5.36 percent to 289.50 DKK. Since the record high achieved more than a year ago with more than 1,000 crowns in the course of the boom at that time about weight loss medication, it has been steeply downhill.
With the Smill injection injection, Novo Nordisk had nevertheless exceeded expectations that this was slightly positive, wrote analyst Richard Vosser from the US bank JPMorgan. However, the focus remains on the long-term prospects for GLP-1 diabetes and weight loss medication. With his “Overweight” recommendation, Vosser remains optimistic. Bank UBS unchanged with “neutral”. Jefferies, on the other hand, is more skeptical with “underperform”.
/TAV/JHA/
BAGSVAERD (dpa-AfX)